Metastatik Renal Hücreli Kanser ve Metastatik Sarkom Tedavisi Sırasında Gelişen Pazopanib İlişkili Makrositoz’un Klinik Önemi-Reference-Cited by-同舟云学术

Metastatik Renal Hücreli Kanser ve Metastatik Sarkom Tedavisi Sırasında Gelişen Pazopanib İlişkili Makrositoz’un Klinik Önemi

Published:2023-08-22 Issue: Volume: Page:
ISSN:2687-2781
Container-title:Akdeniz Medical Journal
language:tr
Short-container-title:Akd Tıp D

Author:

İLHAN Yusuf¹^ORCID,ÖZBAY Mehmet Fatih²^ORCID,GÖKSU Sema Sezgin²^ORCID,TATLI Ali Murat²^ORCID,COŞKUN Hasan Şenol³^ORCID

Affiliation:

1. Tatvan Devlet Hastanesi

2. AKDENİZ ÜNİVERSİTESİ, TIP FAKÜLTESİ

3. Akdeniz Sağlık Vakfı Yaşam Hastanesi

Abstract

Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas (mRCC or mSTS). We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significant of this effect in mRCC or mSTS. Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV >100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: 50 patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.7±7.6 fL, 87.8 ± 7.5, 92.4 ± 8.9, 94.8 ± 11.1 and 99.0 ± 10.7 fL, retrospectively (p

Funder

Yoktur

Publisher

Akdeniz University

Subject

General Medicine

Reference15 articles.

1. REFERENCES 1. Shingo Miyamoto, Shigenori Kakutani, Yujiro Sato, Akira Hanashi, Yoshitaka Kinoshita, Akira Ishikawa, Drug review: Pazopanib, Jpn J Clin Oncol 2018; 48(6):503-13.

2. 2. Schallier D, Trullemans F, Fontaine C, Decoster L, De Greve J. Tyrosine Kinase Inhibitor-induced Macrocytosis, Anticancer Research 2009; 29 (12): 5225-28.

3. 3. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010;29:95.

4. 4. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol. 2012;23(12):3137-43.

5. 5. Huang PW, Chou WC, Shen WC, Hung CY, Huang KG, Su YL, Lu CH, Liu CT, Chang YS, Liau CT. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. Asia Pac J Clin Oncol. 2018;14(4):353-60.